Merit Medical Systems (NASDAQ:MMSI – Get Free Report) issued its earnings results on Thursday. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.08, FiscalAI reports. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%. The firm had revenue of $416.24 million for the quarter, compared to analyst estimates of $410.56 million. During the same period last year, the company earned $0.92 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis.
Here are the key takeaways from Merit Medical Systems’ conference call:
- Strong third-quarter performance: Revenue rose 8% to $416 million, including 9% organic constant-currency growth, while non-GAAP operating margin expanded 160 basis points to 21.3% and EPS increased 22% to $1.12. Free cash flow was nearly $53 million.
- Merit raised its 2026 outlook, now expecting 7.1%–7.6% organic constant-currency revenue growth, non-GAAP EPS of $4.33–$4.37, and a 21.2%–21.4% operating margin. Management said it remains on track to meet its three-year growth initiatives targets.
- Solo Pace acquisition expands the cardiac portfolio: Merit paid approximately $45 million for the remaining equity in the temporary pacing technology company, which serves the growing TAVR market; the deal is expected to be slightly accretive to 2027 earnings.
- Management cited ongoing execution and market risks, including competitive pressure on WRAPSODY, uncertainty surrounding China’s pricing and localization policies, elevated inventory, and lower gross margin from manufacturing variances, platinum costs, and freight. The company expects to address inventory and efficiency through its new chief operating officer’s initiatives.
Merit Medical Systems Stock Up 1.3%
NASDAQ:MMSI traded up $1.18 during trading hours on Thursday, hitting $93.39. 979,227 shares of the company’s stock traded hands, compared to its average volume of 650,489. The firm has a market cap of $5.58 billion, a P/E ratio of 25.12, a P/E/G ratio of 2.30 and a beta of 0.51. Merit Medical Systems has a twelve month low of $59.74 and a twelve month high of $94.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20. The stock’s fifty day moving average price is $88.68 and its two-hundred day moving average price is $77.12.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on MMSI shares. Freedom Capital began coverage on shares of Merit Medical Systems in a report on Tuesday. They set a “hold” rating for the company. BTIG Research reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Merit Medical Systems in a report on Tuesday, August 11th. JPMorgan Chase & Co. increased their price objective on shares of Merit Medical Systems from $77.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Raymond James Financial reiterated an “outperform” rating and issued a $100.00 price objective on shares of Merit Medical Systems in a research report on Friday, July 31st. Finally, Piper Sandler boosted their target price on shares of Merit Medical Systems from $96.00 to $106.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Eight equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $100.00.
Read Our Latest Stock Report on MMSI
Key Headlines Impacting Merit Medical Systems
Here are the key news stories impacting Merit Medical Systems this week:
- Positive Sentiment: Q3 results exceeded expectations. Revenue reached $416.2 million, above the $410.6 million consensus estimate. GAAP EPS was $0.70, up 51% year over year, while non-GAAP EPS was $1.12, topping the $1.04 analyst estimate. Merit Medical earnings report
- Positive Sentiment: Growth and profitability improved. Organic constant-currency revenue increased 9%, GAAP operating margin expanded to 14.1% from 11.1%, and non-GAAP operating margin rose to 21.3% from 19.7%. Year-to-date operating cash flow was $175.2 million and free cash flow was $129.5 million. Merit Medical third-quarter results and guidance
- Positive Sentiment: Full-year guidance was raised. The improved outlook signals management expects demand and operating performance to remain resilient, supporting the earnings-driven move higher. Merit Medical raises outlook
- Positive Sentiment: Cardiac portfolio expanded. Merit Medical acquired Solo Pace, whose temporary pacing technology is designed for patients undergoing treatment for aortic stenosis and is intended to strengthen the company’s transcatheter aortic valve replacement platform. Merit Medical acquires Solo Pace
- Neutral Sentiment: Freedom Capital initiated coverage with a Hold rating. The rating provides limited incremental support and suggests the firm views the stock’s valuation and outlook as broadly balanced. Freedom Capital coverage
- Negative Sentiment: Some insider selling may temper sentiment. The company’s chief operating officer sold 28,949 shares over the past six months, although another senior executive purchased 1,626 shares. These transactions are not directly tied to the quarterly results.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc is a medical device company that develops, manufactures and distributes disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in hospitals, outpatient facilities and other clinical settings.
The company’s product portfolio includes devices for vascular access, angiography, intervention, drainage, embolization, oncology and cardiac procedures. Merit also offers products used in peripheral intervention, spine procedures and other specialized areas of minimally invasive medicine, including kits, accessories and related procedural equipment.
Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves healthcare providers through a global commercial and manufacturing network.
Further Reading
- Five stocks we like better than Merit Medical Systems
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
